2022 Q1: A Tumultuous Start to a Critical Year
- 2022 started much as 2020 and 2021 had ended, with the world in the midst of a new COVID-19 outbreak, this one tied to the much milder Omicron variant. Fortunately, this variant’s emergence as the dominant strain of COVID improved the global health situation enough that countries worldwide began lifting restrictions and returning life to something resembling pre-pandemic normal.
- On top of COVID, the first quarter was defined by the outbreak of armed conflict between Russia and Ukraine, which has had major impacts on the global supply chain for key natural resources such as gas and wheat. Equity markets reflected this negative sentiment, with the S&P 500 and Dow Jones both down during the quarter.
- M&A transaction volume was down from the record pace of 2021’s first quarter, though still at a very healthy level, exceeding 2018 and 2020’s first quarter marks, and down slightly from 2019’’s. Valuation metrics remained advantageous for sellers, with both mean and median TEV / EBITDA multiples up from 2021-year end levels.
- The 4 tracked medical subsector indices all outperformed the benchmark S&P 500 Growth Index, which was down 9.5%, and three of the medical indices outperformed the Dow Jones Industrial Average which was down 5.2%.
Read Medical Technology M&A Pulse Q1 2022 Full Report
Medical Technology M&A Pulse – Q2 2024
Ongoing volatility in the Medical Technology M&A sector is driving heightened diligence and investor scrutiny to ensure acquisition targets are high-quality assets capable of withstanding current market turbulence.
Medical Technology M&A Pulse – Q1 2024
Persistent inflation in Q1 2024 delayed expected rate cuts as the Federal Reserve back tracked expectations from four to three cuts this year.
Medical Technology M&A Pulse – Q4 2023
Concerns about a recession dominated economic discussions in early 2023, fueled by the Federal Reserve’s aggressive response to historically high inflation.
Medical Technology M&A Pulse – Q3 2023
Inflation, while still an economic focal point, is not the sentiment driver it was earlier in the year and in 2022.
Medical Technology M&A Pulse – Q2 2023
One year into an unprecedented cycle of interest rate increases, the task of an economic soft landing, once deemed nearly impossible, appears more and more likely.